Ondine Biomedical (FRA:VF5) Interest Expense : €-0.03 Mil (TTM As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Ondine Biomedical Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Ondine Biomedical's interest expense for the six months ended in Jun. 2024 was € -0.02 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.03 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Ondine Biomedical's Operating Income for the six months ended in Jun. 2024 was € -5.31 Mil. Ondine Biomedical's Interest Expense for the six months ended in Jun. 2024 was € -0.02 Mil. Ondine Biomedical did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Ondine Biomedical Interest Expense Historical Data

The historical data trend for Ondine Biomedical's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ondine Biomedical Interest Expense Chart

Ondine Biomedical Annual Data

Trend

Dec08

Dec09

Dec10

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.12

-0.32

-0.84

-0.02

-0.03

Ondine Biomedical Semi-Annual Data
	Dec07	Jun08	Dec08	Jun09	Dec09	Jun10	Dec10	Jun11	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Interest Expense	Get a 7-Day Free Trial															-0.01	-0.02	-0.01	-0.01	-0.02

Ondine Biomedical Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.03 Mil.

Ondine Biomedical (FRA:VF5) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Ondine Biomedical's Interest Expense for the six months ended in Jun. 2024 was €-0.02 Mil. Its Operating Income for the six months ended in Jun. 2024 was €-5.31 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2024 was €0.00 Mil.

Ondine Biomedical's Interest Coverage for the quarter that ended in Jun. 2024 is calculated as

Ondine Biomedical did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Ondine Biomedical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ondine Biomedical Inc (FRA:VF5) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

OBIMF:USA OBI:UK

Address

1100 Melville Street, Suite 888, Vancouver, BC, CAN, V6E4A6

Website

https://www.ondinebio.com

Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.

Ondine Biomedical Headlines

No Headlines